Nuvalent Inc. is a biopharmaceutical company. It focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. The company's program pipeline includes ROS1-positive and ALK-positive NSCLC. Nuvalent Inc. is based in CAMBRIDGE, Mass.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-425.38M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 6.74 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -39.29% |
| Return on Assets (Trailing 12 Months) | -35.01% |
| Current Ratio (Most Recent Fiscal Quarter) | 15.27 |
| Quick Ratio (Most Recent Fiscal Quarter) | 15.27 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $15.95 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.29 |
| Earnings per Share (Most Recent Fiscal Year) | $-5.85 |
| Diluted Earnings per Share (Trailing 12 Months) | $-5.85 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 78.62M |
| Free Float | 70.60M |
| Market Capitalization | $8.46B |
| Average Volume (Last 20 Days) | 0.58M |
| Beta (Past 60 Months) | 1.31 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 10.20% |
| Percentage Held By Institutions (Latest 13F Reports) | 97.26% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |